 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
1 term
|
 |
|
Biological process
|
immune response
|
1 term
|
 |
|
Biochemical function
|
tumor necrosis factor receptor binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Structure
3:1031-1039
(1995)
|
|
PubMed id:
|
|
|
|
|
| |
|
2 A crystal structure of an extracellular fragment of human CD40 ligand.
|
|
M.Karpusas,
Y.M.Hsu,
J.H.Wang,
J.Thompson,
S.Lederman,
L.Chess,
D.Thomas.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: The CD40 ligand (CD40L) is a member of the tumor necrosis factor
(TNF) family of proteins and is transiently expressed on the surface of
activated T cells. The binding of CD40L to CD40, which is expressed on the
surface of B cells, provides a critical and unique pathway of cellular
activation resulting in antibody isotype switching, regulation of apoptosis, and
B cell proliferation and differentiation. Naturally occurring mutations of CD40L
result in the clinical hyper-IgM syndrome, characterized by an inability to
produce immunoglobulins of the IgG, IgA and IgE isotypes. RESULTS: We have
determined the crystal structure of a soluble extracellular fragment of human
CD40L to 2 A resolution and with an R factor of 21.8%. Although the molecule
forms a trimer similar to that found for other members of the TNF family, such
as TNF alpha and lymphotoxin-alpha, and exhibits a similar overall fold, there
are considerable differences in several loops including those predicted to be
involved in CD40 binding. CONCLUSIONS: The structure suggests that most of the
hyper-IgM syndrome mutations affect the folding and stability of the molecule
rather than the CD40-binding site directly. Despite the fact that the hyper-IgM
syndrome mutations are dispersed in the primary sequence, a large fraction of
them are clustered in space in the vicinity of a surface loop, close to the
predicted CD40-binding site.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Representative regions of the final 2F[o]–F[c]
electron density map contoured at 2.5σ. (a) Residues in the
vicinity of the CD40 binding site. (b) View of a cluster of
three tyrosine and three histidine residues formed in the
vicinity of the center of the trimer. The threefold axis is
vertical. Figure 1. Representative regions of the final
2F[o]–F[c] electron density map contoured at 2.5σ. (a)
Residues in the vicinity of the CD40 binding site. (b) View of a
cluster of three tyrosine and three histidine residues formed in
the vicinity of the center of the trimer. The threefold axis is
vertical.
|
 |
Figure 3.
Figure 3. Stereo diagram of superimposed Cα backbones of TNFα
(green), LTα (blue) and CD40L (red) crystal structures. The
view is approximately the same as in Figure 2. Figure 3.
Stereo diagram of superimposed Cα backbones of TNFα (green),
LTα (blue) and CD40L (red) crystal structures. The view is
approximately the same as in [3]Figure 2.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Structure
(1995,
3,
1031-1039)
copyright 1995.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.P.Hsu,
T.A.Fleisher,
and
J.E.Niemela
(2009).
Mutation analysis in primary immunodeficiency diseases: case studies.
|
| |
Curr Opin Allergy Clin Immunol, 9,
517-524.
|
 |
|
|
|
|
 |
N.Guex,
M.C.Peitsch,
and
T.Schwede
(2009).
Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective.
|
| |
Electrophoresis, 30,
S162-S173.
|
 |
|
|
|
|
 |
R.Elgueta,
M.J.Benson,
V.C.de Vries,
A.Wasiuk,
Y.Guo,
and
R.J.Noelle
(2009).
Molecular mechanism and function of CD40/CD40L engagement in the immune system.
|
| |
Immunol Rev, 229,
152-172.
|
 |
|
|
|
|
 |
Y.C.Tang,
M.Thoman,
P.J.Linton,
and
A.Deisseroth
(2009).
Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.
|
| |
Cancer Immunol Immunother, 58,
1949-1957.
|
 |
|
|
|
|
 |
C.Léveillé,
M.Bouillon,
W.Guo,
J.Bolduc,
E.Sharif-Askari,
Y.El-Fakhry,
C.Reyes-Moreno,
R.Lapointe,
Y.Merhi,
J.A.Wilkins,
and
W.Mourad
(2007).
CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling.
|
| |
J Biol Chem, 282,
5143-5151.
|
 |
|
|
|
|
 |
H.C.Shin,
and
K.H.Cho
(2005).
Mutational analysis of human tumor necrosis factor-alpha.
|
| |
Biotechnol Lett, 27,
107-112.
|
 |
|
|
|
|
 |
M.L.Narasimhan,
M.A.Coca,
J.Jin,
T.Yamauchi,
Y.Ito,
T.Kadowaki,
K.K.Kim,
J.M.Pardo,
B.Damsz,
P.M.Hasegawa,
D.J.Yun,
and
R.A.Bressan
(2005).
Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor.
|
| |
Mol Cell, 17,
171-180.
|
 |
|
|
|
|
 |
S.Bouralexis,
D.M.Findlay,
and
A.Evdokiou
(2005).
Death to the bad guys: targeting cancer via Apo2L/TRAIL.
|
| |
Apoptosis, 10,
35-51.
|
 |
|
|
|
|
 |
S.Fournel,
S.Wieckowski,
W.Sun,
N.Trouche,
H.Dumortier,
A.Bianco,
O.Chaloin,
M.Habib,
J.C.Peter,
P.Schneider,
B.Vray,
R.E.Toes,
R.Offringa,
C.J.Melief,
J.Hoebeke,
and
G.Guichard
(2005).
C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L.
|
| |
Nat Chem Biol, 1,
377-382.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
and
A.Ashkenazi
(2005).
Toward small-molecule agonists of TNF receptors.
|
| |
Nat Chem Biol, 1,
353-354.
|
 |
|
|
|
|
 |
S.Réty,
S.Salamitou,
I.Garcia-Verdugo,
D.J.Hulmes,
F.Le Hégarat,
R.Chaby,
and
A.Lewit-Bentley
(2005).
The crystal structure of the Bacillus anthracis spore surface protein BclA shows remarkable similarity to mammalian proteins.
|
| |
J Biol Chem, 280,
43073-43078.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Etzioni,
and
H.D.Ochs
(2004).
The hyper IgM syndrome--an evolving story.
|
| |
Pediatr Res, 56,
519-525.
|
 |
|
|
|
|
 |
G.Eissner,
W.Kolch,
and
P.Scheurich
(2004).
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.
|
| |
Cytokine Growth Factor Rev, 15,
353-366.
|
 |
|
|
|
|
 |
G.Zhang
(2004).
Tumor necrosis factor family ligand-receptor binding.
|
| |
Curr Opin Struct Biol, 14,
154-160.
|
 |
|
|
|
|
 |
S.Shankar,
and
R.K.Srivastava
(2004).
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications.
|
| |
Drug Resist Updat, 7,
139-156.
|
 |
|
|
|
|
 |
T.Mori,
A.Oguro,
T.Ohtsu,
and
Y.Nakamura
(2004).
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.
|
| |
Nucleic Acids Res, 32,
6120-6128.
|
 |
|
|
|
|
 |
Y.Fan,
Y.Ge,
H.Zhu,
Y.Wang,
B.Yang,
Y.Zhuang,
H.Ma,
and
X.Zhang
(2004).
Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L.
|
| |
Tissue Antigens, 64,
257-263.
|
 |
|
|
|
|
 |
K.Pfeffer
(2003).
Biological functions of tumor necrosis factor cytokines and their receptors.
|
| |
Cytokine Growth Factor Rev, 14,
185-191.
|
 |
|
|
|
|
 |
M.I.Vega,
L.Santos-Argumedo,
S.Huerta-Yepez,
R.Luría-Perez,
V.Ortiz-Navarrete,
A.Isibasi,
and
C.R.González-Bonilla
(2003).
A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.
|
| |
Immunology, 110,
206-216.
|
 |
|
|
|
|
 |
Y.Liu,
X.Hong,
J.Kappler,
L.Jiang,
R.Zhang,
L.Xu,
C.H.Pan,
W.E.Martin,
R.C.Murphy,
H.B.Shu,
S.Dai,
and
G.Zhang
(2003).
Ligand-receptor binding revealed by the TNF family member TALL-1.
|
| |
Nature, 423,
49-56.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Ashkenazi
(2002).
Targeting death and decoy receptors of the tumour-necrosis factor superfamily.
|
| |
Nat Rev Cancer, 2,
420-430.
|
 |
|
|
|
|
 |
D.A.Oren,
Y.Li,
Y.Volovik,
T.S.Morris,
C.Dharia,
K.Das,
O.Galperina,
R.Gentz,
and
E.Arnold
(2002).
Structural basis of BLyS receptor recognition.
|
| |
Nat Struct Biol, 9,
288-292.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.L.Bodmer,
P.Schneider,
and
J.Tschopp
(2002).
The molecular architecture of the TNF superfamily.
|
| |
Trends Biochem Sci, 27,
19-26.
|
 |
|
|
|
|
 |
P.Cappello,
F.Novelli,
G.Forni,
and
M.Giovarelli
(2002).
Death receptor ligands in tumors.
|
| |
J Immunother (1997), 25,
1.
|
 |
|
|
|
|
 |
S.Ito,
K.Wakabayashi,
O.Ubukata,
S.Hayashi,
F.Okada,
and
T.Hata
(2002).
Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution.
|
| |
J Biol Chem, 277,
6631-6636.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.G.Werneburg,
S.J.Zoog,
T.T.Dang,
M.R.Kehry,
and
J.J.Crute
(2001).
Molecular characterization of CD40 signaling intermediates.
|
| |
J Biol Chem, 276,
43334-43342.
|
 |
|
|
|
|
 |
J.Lam,
C.A.Nelson,
F.P.Ross,
S.L.Teitelbaum,
and
D.H.Fremont
(2001).
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.
|
| |
J Clin Invest, 108,
971-979.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.E.Haswell,
M.J.Glennie,
and
A.Al-Shamkhani
(2001).
Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154.
|
| |
Eur J Immunol, 31,
3094-3100.
|
 |
|
|
|
|
 |
M.Karpusas,
J.Lucci,
J.Ferrant,
C.Benjamin,
F.R.Taylor,
K.Strauch,
E.Garber,
and
Y.M.Hsu
(2001).
Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.
|
| |
Structure, 9,
321-329.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.K.Srivastava
(2001).
TRAIL/Apo-2L: mechanisms and clinical applications in cancer.
|
| |
Neoplasia, 3,
535-546.
|
 |
|
|
|
|
 |
B.Barnhart,
G.S.Ford,
A.Bhushan,
C.Song,
and
L.R.Covey
(2000).
A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions.
|
| |
Immunology, 99,
54-61.
|
 |
|
|
|
|
 |
B.Berner,
G.Wolf,
K.M.Hummel,
G.A.Müller,
and
M.A.Reuss-Borst
(2000).
Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis.
|
| |
Ann Rheum Dis, 59,
190-195.
|
 |
|
|
|
|
 |
E.Y.Jones
(2000).
The tumour necrosis factor receptor family: life or death choices.
|
| |
Curr Opin Struct Biol, 10,
644-648.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
M.P.O'Connell,
M.H.Ultsch,
A.Hurst,
K.Totpal,
A.Ashkenazi,
A.M.de Vos,
and
R.F.Kelley
(2000).
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.
|
| |
Biochemistry, 39,
633-640.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
U.Schönbeck,
F.Mach,
and
P.Libby
(2000).
CD154 (CD40 ligand).
|
| |
Int J Biochem Cell Biol, 32,
687-693.
|
 |
|
|
|
|
 |
A.E.Morris,
R.L.Remmele,
R.Klinke,
B.M.Macduff,
W.C.Fanslow,
and
R.J.Armitage
(1999).
Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).
|
| |
J Biol Chem, 274,
418-423.
|
 |
|
|
|
|
 |
E.A.Webster,
A.Y.Khakoo,
W.J.Mackus,
M.Karpusas,
D.W.Thomas,
A.Davidson,
C.L.Christian,
and
S.Lederman
(1999).
An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM syndrome).
|
| |
Arthritis Rheum, 42,
1291-1296.
|
 |
|
|
|
|
 |
E.Garber,
L.Su,
B.Ehrenfels,
M.Karpusas,
and
Y.M.Hsu
(1999).
CD154 variants associated with hyper-IgM syndrome can form oligomers and trigger CD40-mediated signals.
|
| |
J Biol Chem, 274,
33545-33550.
|
 |
|
|
|
|
 |
J.Bajorath
(1999).
Identification of the ligand binding site in Fas (CD95) and analysis of Fas-ligand interactions.
|
| |
Proteins, 35,
475-482.
|
 |
|
|
|
|
 |
K.Seyama,
W.R.Osborne,
and
H.D.Ochs
(1999).
CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand.
|
| |
J Biol Chem, 274,
11310-11320.
|
 |
|
|
|
|
 |
R.K.Vakkalanka,
C.Woo,
K.A.Kirou,
M.Koshy,
D.Berger,
and
M.K.Crow
(1999).
Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera.
|
| |
Arthritis Rheum, 42,
871-881.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
H.W.Christinger,
G.Fuh,
M.Ultsch,
M.O'Connell,
R.F.Kelley,
A.Ashkenazi,
and
A.M.de Vos
(1999).
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
|
| |
Mol Cell, 4,
563-571.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.M.McWhirter,
S.S.Pullen,
B.G.Werneburg,
M.E.Labadia,
R.H.Ingraham,
J.J.Crute,
M.R.Kehry,
and
T.Alber
(1999).
Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins.
|
| |
Cold Spring Harb Symp Quant Biol, 64,
551-562.
|
 |
|
|
|
|
 |
S.M.McWhirter,
S.S.Pullen,
J.M.Holton,
J.J.Crute,
M.R.Kehry,
and
T.Alber
(1999).
Crystallographic analysis of CD40 recognition and signaling by human TRAF2.
|
| |
Proc Natl Acad Sci U S A, 96,
8408-8413.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.S.Cha,
H.C.Shin,
K.Y.Choi,
and
B.H.Oh
(1999).
Expression, purification and crystallization of recombinant human TRAIL.
|
| |
Acta Crystallogr D Biol Crystallogr, 55,
1101-1104.
|
 |
|
|
|
|
 |
S.S.Cha,
M.S.Kim,
Y.H.Choi,
B.J.Sung,
N.K.Shin,
H.C.Shin,
Y.C.Sung,
and
B.H.Oh
(1999).
2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity.
|
| |
Immunity, 11,
253-261.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.S.Pullen,
M.E.Labadia,
R.H.Ingraham,
S.M.McWhirter,
D.S.Everdeen,
T.Alber,
J.J.Crute,
and
M.R.Kehry
(1999).
High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.
|
| |
Biochemistry, 38,
10168-10177.
|
 |
|
|
|
|
 |
I.D.Campbell
(1998).
The modular architecture of leukocyte cell-surface receptors.
|
| |
Immunol Rev, 163,
11-18.
|
 |
|
|
|
|
 |
J.Bajorath
(1998).
Detailed comparison of two molecular models of the human CD40 ligand with an x-ray structure and critical assessment of model-based mutagenesis and residue mapping studies.
|
| |
J Biol Chem, 273,
24603-24609.
|
 |
|
|
|
|
 |
J.Singh,
E.Garber,
H.Van Vlijmen,
M.Karpusas,
Y.M.Hsu,
Z.Zheng,
J.H.Naismith,
and
D.Thomas
(1998).
The role of polar interactions in the molecular recognition of CD40L with its receptor CD40.
|
| |
Protein Sci, 7,
1124-1135.
|
 |
|
|
|
|
 |
L.Shapiro,
and
P.E.Scherer
(1998).
The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor.
|
| |
Curr Biol, 8,
335-338.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Al-Shamkhani,
S.Mallett,
M.H.Brown,
W.James,
and
A.N.Barclay
(1997).
Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells.
|
| |
J Biol Chem, 272,
5275-5282.
|
 |
|
|
|
|
 |
B.Zheng,
S.Han,
Y.Takahashi,
and
G.Kelsoe
(1997).
Immunosenescence and germinal center reaction.
|
| |
Immunol Rev, 160,
63-77.
|
 |
|
|
|
|
 |
J.R.Orlinick,
K.B.Elkon,
and
M.V.Chao
(1997).
Separate domains of the human fas ligand dictate self-association and receptor binding.
|
| |
J Biol Chem, 272,
32221-32229.
|
 |
|
|
|
|
 |
P.Schneider,
J.L.Bodmer,
N.Holler,
C.Mattmann,
P.Scuderi,
A.Terskikh,
M.C.Peitsch,
and
J.Tschopp
(1997).
Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.
|
| |
J Biol Chem, 272,
18827-18833.
|
 |
|
|
|
|
 |
R.F.Schwabe,
S.Hess,
J.P.Johnson,
and
H.Engelmann
(1997).
Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies.
|
| |
Hybridoma, 16,
217-226.
|
 |
|
|
|
|
 |
S.K.Datta,
and
S.L.Kalled
(1997).
CD40-CD40 ligand interaction in autoimmune disease.
|
| |
Arthritis Rheum, 40,
1735-1745.
|
 |
|
|
|
|
 |
Y.M.Hsu,
J.Lucci,
L.Su,
B.Ehrenfels,
E.Garber,
and
D.Thomas
(1997).
Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes.
|
| |
J Biol Chem, 272,
911-915.
|
 |
|
|
|
|
 |
H.J.Gruss
(1996).
Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily.
|
| |
Int J Clin Lab Res, 26,
143-159.
|
 |
|
|
|
|
 |
J.Bajorath,
K.Seyama,
S.Nonoyama,
H.D.Ochs,
and
A.Aruffo
(1996).
Classification of mutations in the human CD40 ligand, gp39, that are associated with X-linked hyper IgM syndrome.
|
| |
Protein Sci, 5,
531-534.
|
 |
|
|
|
|
 |
J.L.Browning,
K.Miatkowski,
D.A.Griffiths,
P.R.Bourdon,
C.Hession,
C.M.Ambrose,
and
W.Meier
(1996).
Preparation and characterization of soluble recombinant heterotrimeric complexes of human lymphotoxins alpha and beta.
|
| |
J Biol Chem, 271,
8618-8626.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|